Saturday, 10 October 2026European Markets

SALMONES CAMANCHAC Stock 14.65% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with SALMONES CAMANCHAC (SACAM.OL) rising 14.65% to kr18.00 on Friday while Oslo Børs Benchmark Index_GI rose 0.46% to kr1,422.35.

SALMONES CAMANCHAC's last close was kr15.70, 67.15% below its 52-week high of kr47.80.

About SALMONES CAMANCHAC

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. Salmones Camanchaca S.A. was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. is a subsidiary of Camanchaca S.A.

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-2.17.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -7.32%.

Sales Growth

SALMONES CAMANCHAC's sales growth is 64.2% for the present quarter and 12.9% for the next.

More news about SALMONES CAMANCHAC (SACAM.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com